# Who are Olympus's customers? Who does Olympus earn revenue from?
Canonical: https://valuechain.wiki/olympus · Facet: customers · Updated: 2026-10-13T17:25:44.083912+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Olympus discloses no named confirmed revenue counterparties; 2 relationships are tracked as undisclosed/aggregate. Per the valuechain.wiki graph: 2 revenue edges, backed by 3 dated sources, 1 of them primary filings (as of 2026-10-13).

### 소화기 솔루션 고객 (병원·의료기관) (high)
- metric: Amount 168,448 JPY_million · FY2027 Q1 · Gastrointestinal Solutions revenue
- note: Olympus supplies endoscopy, endotherapy and services to hospitals and care providers. FY2027 Q1 Gastrointestinal Solutions revenue rose 21.2% to JPY168.448 billion.
- [confirms] Olympus Corporation (EN, filing, published 2026-08-07) https://www.olympus-global.com/ir/data/brief/pdf/01_tanshin_Q1FY2027_en.pdf: "The filing reports FY2027 Q1 Gastrointestinal Solutions revenue of JPY168.448 billion, up 21.2%."
- [mentions] Dailypharm (KO, news, published 2026-07-08) https://www.dailypharm.com/user/news/340215?view_mode=kakao: "Dailypharm reports concurrent growth in Olympus Korea product and service sales and an expanding therapy portfolio."
- [mentions] Samsung Securities (KO, research, published 2024-09-10) https://www.samsungpop.com/common.do?cmd=down&contentType=application/pdf&fileName=2020/2024091010184252K_02_05.pdf&inlineYn=Y&saveKey=research.pdf: "Samsung Securities describes the endoscopy-equipment market as concentrated among optical-device leaders including Olympus."

### 외과·중재 솔루션 고객 (병원·의료기관) (high)
- metric: Amount 71,923 JPY_million · FY2027 Q1 · Surgical & Interventional Solutions revenue
- note: Olympus supplies urology, respiratory and surgical-endoscopy products to hospitals and care providers. FY2027 Q1 division revenue rose 6.7% to JPY71.923 billion.
- [confirms] Olympus Corporation (EN, filing, published 2026-08-07) https://www.olympus-global.com/ir/data/brief/pdf/01_tanshin_Q1FY2027_en.pdf: "The filing reports FY2027 Q1 Surgical & Interventional Solutions revenue of JPY71.923 billion, up 6.7%."
- [mentions] Samsung Securities (KO, research, published 2024-09-10) https://www.samsungpop.com/common.do?cmd=down&contentType=application/pdf&fileName=2020/2024091010184252K_02_05.pdf&inlineYn=Y&saveKey=research.pdf: "Samsung Securities identifies endoscopy, non-vascular stents and laparoscopy as core minimally invasive gastrointestinal-device markets."

Reverse side: https://valuechain.wiki/olympus/suppliers.md · Ripple: https://valuechain.wiki/olympus/ripple.md

---
Full node: https://valuechain.wiki/olympus.md · JSON: https://valuechain.wiki/olympus.json